claudin 13 Inhibitors
The chemical class of claudin 13 inhibitors comprises compounds targeting the integral membrane protein involved in tight junction strands. Occludin Inhibitor directly disrupts the interaction between occludin and claudin 13, hindering tight junction formation and impacting paracellular permeability. Aurothioglucose acts as a direct inhibitor, influencing the structure of claudin 13-containing tight junctions and compromising their physical barrier function. Nystatin disrupts membrane integrity and impacts lipid composition, directly affecting claudin 13's role in maintaining tight junction dynamics. Quercetin, an indirect inhibitor, modulates cellular signaling pathways related to tight junction regulation and cell polarity, indirectly influencing claudin 13 expression and function. EGFR Inhibitor indirectly affects claudin 13 by inhibiting EGFR and modulating downstream signaling pathways, impacting tight junction dynamics and paracellular permeability. Chelerythrine acts as a direct inhibitor by influencing the phosphorylation status of claudin 13 through PKC modulation, affecting tight junction structure and function.
GSK-3 Inhibitor, an indirect inhibitor, targets GSK-3 to influence downstream signaling pathways involved in tight junction regulation and claudin 13 expression. Staurosporine directly impacts claudin 13 by affecting its phosphorylation status, disrupting tight junction structure and compromising physical barrier function. ML-7 acts as a direct inhibitor, modulating MLCK activity to influence the contractility of tight junctions containing claudin 13. Genistein, an indirect inhibitor, influences signaling pathways related to tight junction regulation and claudin 13 expression. Calphostin C acts as a direct inhibitor by modulating PKC activity, affecting the phosphorylation status of claudin 13 and disrupting tight junction structure. Wortmannin, an indirect inhibitor, targets PI3K activity to modulate downstream pathways involved in tight junction regulation and claudin 13 expression. Collectively, these inhibitors provide valuable insights into potential strategies for pharmacological modulation of claudin 13, shedding light on its crucial role in tight junction dynamics and cellular processes associated with paracellular transport and cell polarity maintenance. The detailed understanding of these inhibitors' mechanisms allows for a more targeted approach in investigating claudin 13 functions and their implications for cellular regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Nystatin | 1400-61-9 | sc-212431 sc-212431A sc-212431B sc-212431C | 5 MU 25 MU 250 MU 5000 MU | $50.00 $126.00 $246.00 $3500.00 | 7 | |
Nystatin acts as a direct inhibitor of claudin 13 by disrupting membrane integrity. It influences the lipid composition of tight junctions containing claudin 13, affecting their structure and compromising the physical barrier function. This leads to altered paracellular permeability and perturbed signaling pathways associated with claudin 13 in maintaining cell polarity. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $108.00 $245.00 $918.00 $49.00 | 33 | |
Quercetin serves as an indirect inhibitor of claudin 13 by modulating cellular signaling pathways. As a flavonoid, it impacts pathways involved in tight junction regulation and cell polarity, indirectly influencing the expression and function of claudin 13. This leads to altered tight junction dynamics and paracellular permeability, affecting the physical barrier function of claudin 13-containing junctions. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $88.00 $311.00 | 17 | |
Chelerythrine serves as a direct inhibitor of claudin 13 by affecting tight junction strands. By modulating protein kinase C (PKC) activity, it influences the phosphorylation status of claudin 13, directly impacting its function in tight junctions. This leads to altered paracellular permeability and compromised physical barrier function, affecting cell polarity and signal transduction pathways associated with claudin 13. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $57.00 $184.00 $867.00 | 10 | |
GSK-3 Inhibitor acts as an indirect inhibitor of claudin 13 by targeting glycogen synthase kinase-3 (GSK-3). By modulating GSK-3 activity, it influences downstream signaling pathways involved in tight junction regulation and claudin 13 expression. This leads to altered tight junction dynamics, affecting the physical barrier function and paracellular permeability associated with claudin 13-containing junctions. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine serves as a direct inhibitor of claudin 13 by influencing tight junction strands. As a non-selective protein kinase inhibitor, it impacts the phosphorylation status of claudin 13, directly affecting its function in tight junctions. This leads to altered paracellular permeability and compromised physical barrier function, influencing cell polarity and signaling pathways associated with claudin 13. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $89.00 $262.00 | 13 | |
ML-7 acts as a direct inhibitor of claudin 13 by modulating myosin light chain kinase (MLCK) activity. By influencing the phosphorylation status of myosin, it directly impacts the contractility of tight junctions containing claudin 13, affecting their structure and physical barrier function. This leads to altered paracellular permeability and compromised cell polarity maintenance associated with claudin 13-containing junctions. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein serves as an indirect inhibitor of claudin 13 by influencing signaling pathways. As a tyrosine kinase inhibitor, it modulates pathways involved in tight junction regulation and claudin 13 expression. This leads to altered tight junction dynamics, affecting the physical barrier function and paracellular permeability associated with claudin 13-containing junctions. | ||||||
Calphostin C | 121263-19-2 | sc-3545 sc-3545A | 100 µg 1 mg | $336.00 $1642.00 | 20 | |
Calphostin C acts as a direct inhibitor of claudin 13 by modulating protein kinase C (PKC) activity. By influencing the phosphorylation status of claudin 13, it directly impacts its function in tight junctions. This leads to altered paracellular permeability and compromised physical barrier function, influencing cell polarity and signal transduction pathways associated with claudin 13. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin serves as an indirect inhibitor of claudin 13 by targeting phosphoinositide 3-kinase (PI3K) activity. By modulating PI3K signaling, it influences downstream pathways involved in tight junction regulation and claudin 13 expression. This leads to altered tight junction dynamics, affecting the physical barrier function and paracellular permeability associated with claudin 13-containing junctions. | ||||||